Cerebrospinal fluid neurogranin in Alzheimer’s disease studies: are immunoassay results interchangeable?-Reference-Cited by-同舟云学术

Cerebrospinal fluid neurogranin in Alzheimer’s disease studies: are immunoassay results interchangeable?

Published:2021-09-15 Issue:1 Volume:60 Page:e13-e17
ISSN:1434-6621
Container-title:Clinical Chemistry and Laboratory Medicine (CCLM)
language:en
Short-container-title:

Author:

Aveneau Clément¹,Hourregue Claire¹,Cognat Emmanuel¹,Dumurgier Julien¹,Vanderstichele Hugo²,Vanmechelen Eugeen²,Zetterberg Henrik³,Hugon Jacques¹,Blennow Kaj³,Paquet Claire¹,Bouaziz-Amar Elodie⁴

Affiliation:

1. Centre de Neurologie Cognitive, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Université de Paris , Paris , France

2. ADx NeuroSciences , Gent , Belgium

3. Clinical Neurochemistry Laboratory , Sahlgrenska University Hospital , Gothenburg , Sweden

4. Département de Biochimie , Université de Paris, GHU AP-HP Nord, Hôpital Lariboisière Fernand-Widal, Paris , France

Publisher

Walter de Gruyter GmbH

Subject

Biochemistry, medical,Clinical Biochemistry,General Medicine

Link

https://www.degruyter.com/document/doi/10.1515/cclm-2021-0505/pdf

Reference10 articles.

1. Terry, RD, Masliah, E, Salmon, DP, Butters, N, DeTeresa, R, Hill, R, et al.. Physical basis of cognitive alterations in Alzheimer’s disease: synapse loss is the major correlate of cognitive impairment. Ann Neurol 1991;30:572–80. https://doi.org/10.1002/ana.410300410.

2. de Wilde, MC, Overk, CR, Sijben, JW, Masliah, E. Meta-analysis of synaptic pathology in Alzheimer’s disease reveals selective molecular vesicular machinery vulnerability. Alzheimers Dement 2016;12:633–44. https://doi.org/10.1016/j.jalz.2015.12.005.

3. Kester, MI, Teunissen, CE, Crimmins, DL, Herries, EM, Ladenson, JH, Scheltens, P, et al.. Neurogranin as a cerebrospinal fluid biomarker for synaptic loss in symptomatic Alzheimer disease. JAMA Neurol 2015;72:1275. https://doi.org/10.1001/jamaneurol.2015.1867.

4. Kvartsberg, H, Duits, FH, Ingelsson, M, Andreasen, N, Öhrfelt, A, Andersson, K, et al.. Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer’s disease. Alzheimers Dement 2015;11:1180–90. https://doi.org/10.1016/j.jalz.2014.10.009.

5. Tarawneh, R, D’Angelo, G, Crimmins, D, Herries, E, Griest, T, Fagan, AM, et al.. Diagnostic and prognostic utility of the synaptic marker neurogranin in Alzheimer disease. JAMA Neurol 2016;73:561. https://doi.org/10.1001/jamaneurol.2016.0086.